NCT05749289View on ClinicalTrials.gov

Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

December 20, 2022

Primary Completion Date

December 20, 2024

Study Completion Date

December 20, 2025

Conditions
Neuroendocrine Tumor
Interventions
DRUG

Al18F-octreotide

Al18F-octreotide I was injected into the patients before the PET/CT scans

Trial Locations (1)

100021

RECRUITING

National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER